Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cholestasis is a major hepatic disease in infants, with increasing morbidity in recent years. Accumulating evidence has revealed that the gut microbiota (GM) is associated with liver diseases, such as non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, GM alterations in cholestatic infants and the correlation between the GM and hepatic functions remain uninvestigated. In this study, 43 cholestatic infants (IC group) and 37 healthy infants (H group) were enrolled to detect GM discrepancies using 16S rDNA analysis. The diversity in the bacterial community was significantly lower in the IC group than that in the H group ( = 0.013). After determining the top 10 abundant genera of microbes in the IC and H groups, we found that 13 of them were differentially enriched, including , and . As compared with the H group, the IC group had a more complex GM co-occurrence network featured by three core nodes: , and . In addition, the positive correlation between and ( = 0.689, = 0.000, FDR = 0.009) was not observed in the IC patients. Using the GM composition, the cholestatic patients can be distinguished from healthy infants with high accuracy [areas under receiver operating curve (AUC) > 0.97], wherein , and are identified as valuable biomarkers. Using KEGG annotation, we identified 32 functional categories with significant difference in enrichment of the GM of IC patients, including IC-enriched functional categories that were related to lipid metabolism, biodegradation and metabolism of xenobiotics, and various diseases. In contrast, the number of functions associated with amino acid metabolism, nucleotide metabolism, and vitamins metabolism was reduced in the IC patients. We also identified significant correlation between GM composition and indicators of hepatic function. positively correlated with total bilirubin ( = 0.455, = 0.002) and direct bilirubin ( = 0.441, = 0.003), whereas γ-glutamyl transpeptidase was positively associated with ( = 0.466, = 0.002) and negatively related to ( = -0.450, = 0.003). This study describes the GM characteristics in the cholestatic infants, illustrates the association between the GM components and the hepatic function, and provides a solid theoretical basis for GM intervention for the treatment of infantile cholestasis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243132PMC
http://dx.doi.org/10.3389/fmicb.2018.02682DOI Listing

Publication Analysis

Top Keywords

cholestatic infants
16
hepatic function
12
gut microbiota
8
infants correlation
8
correlation hepatic
8
infants group
8
healthy infants
8
group group
8
functional categories
8
infants
7

Similar Publications

Objective: Phenobarbital is an inductor of microsomal hepatic enzyme and used as choleretic for cholestatic liver disease to enhance bile flow. It is also used as a premedication for hepatobiliary scintigraphy (HIDA) scan to improve diagnostic accuracy for an obstructive liver disease. We reviewed the available literature on the use of Phenobarbital for treatment of cholestasis and its utility as a premedication for HIDA scan.

View Article and Find Full Text PDF

Introduction: Biliary atresia (BA) is a progressive cholestatic disease in neonates and infants, and early diagnosis and treatment significantly impact prognosis. Definitive diagnosis is based on cholangiogram findings, classifying BA into three main types. Among its variants, type I-b1-β-where the common bile duct is blocked, the distal duct is fibrous, and the tiny intrahepatic ducts are underdeveloped-is particularly rare.

View Article and Find Full Text PDF

Introduction: Cholestasis in childhood is a rare clinical condition, yet a definitive diagnosis is crucial for initiating treatment of these curable diseases and preventing related morbidity and mortality. The most common cause of infant cholestasis is biliary atresia (25-40%), followed by monogenic cholestatic diseases (25%), metabolic diseases (20%), and cryptogenic cholestasis. This study focuses on assessing the clinical utility of next-generation sequencing (NGS) panels, including clinical exome sequencing and whole exome sequencing, in diagnosing cholestatic diseases when the etiology cannot be elucidated through conventional methods.

View Article and Find Full Text PDF

New hope in treating progressive familial intrahepatic cholestasis in children.

World J Hepatol

July 2025

Division of Pediatric Gastroenterology, Sheikh Khalifa Medical City, Abu Dhabi 51900, United Arab Emirates.

Progressive familial intrahepatic cholestasis (PFIC) is a group of rare, inherited cholestatic liver disorders presenting in infants and children and are associated with impaired bile flow (, cholestasis), pruritus and progressive liver disease. Historically there has been no effective or approved pharmacologic treatments for these disorders and standard medical treatment has only been supportive. The impaired bile flow within the liver, leads to accumulation in the liver and inflammation.

View Article and Find Full Text PDF

Objectives: Cholestasis in infancy poses a complex clinical conundrum for pediatric hepatologists, warranting timely diagnosis, especially for genetic diseases. This study aims to create machine learning (ML)-based prediction models, referred to as Jaundice Diagnosis Easy for Baby (JADE-B), to identify the subjects prone to genetic causes of cholestasis.

Methods: We retrieved patient data from the Integrated Medical Database at a university-affiliated tertiary medical center from 2006 to 2018.

View Article and Find Full Text PDF